

Number	COMPETENCY The student should be able to	Domain K/S/A/C	Level K/KH/S H/P
--------	---	-------------------	---------------------

Topic: Acne

Number of competencies:(03

DR1.1	Enumerate the causative and risk factors of acne	K	K
DR1.2	Identify and grade the various common types of acne	S	SH
DR1.3	Describe the treatment and preventive measures for various kinds of acne	K	K

Topic: Vitiligo

DR2.1	Demonstrate knowledge of the causes, mechanisms, types and effects of cell injury and their clinical significance	K	KH
DR2.2	Describe the treatment of vitiligo	K	K

Topic: Papulo squamous disorders

Number of co

DR3.1	Identify and distinguish psoriatic lesions from other causes	K	SH
DR3.2	Demonstrate the grattage test	S	SH

DR3.3	Enumerate the indications for and describe the various modalities of treatment of psoriasis including topical, systemic and phototherapy	K	KH
-------	--	---	----

Topic: Lichen Planus

Number of compe

DR4.1	Identify and distinguish lichen planus lesions from other causes	S	SH
DR4.2	Enumerate and describe the treatment modalities for lichen planus	K	KH

Topic: Scabies

DR5.1	Describe the etiology, microbiology, pathogenesis, natural history, clinical features, presentations and complications of scabies in adults and children	K	KH
-------	--	---	----

DR5.2	Identify and differentiate scabies from other lesions in adults and children	S	SH
DR5.3	Enumerate and describe the pharmacology, administration and adverse reaction of pharmacotherapies for scabies	K	KH

Topic: Pediculosis

DR6.1	Describe the etiology pathogenesis and diagnostic features of pediculosis in adults and children	K	KH
DR6.2	Identify and differentiate pediculosis from other skin lesions in adults and children	S	SH

Topic: Fungal Infections

DR7.1	Describe the etiology, microbiology, pathogenesis and clinical presentations and diagnostic features of dermatophytes in adults and children	K	KH
DR7.2	Identify Candida species in fungal scrapings and KOH mount	S	SH
DR7.3	Describe the pharmacology and action of antifungal (systemic and topical) agents. Enumerate side effects of antifungal therapy	K	KH

Topic: Viral infections

DR8.1	Describe the etiology, microbiology, pathogenesis and clinical presentations and diagnostic features of common viral infections of the skin in adults and children	K	KH
-------	--	---	----

DR8.2	Identify and distinguish herpes simplex and herpes labialis from other skin lesions	S	SH
DR8.3	Identify and distinguish herpes zoster and varicella from other skin lesions	S	SH
DR8.4	Identify and distinguish viral warts from other skin lesions	S	SH
DR8.5	Identify and distinguish molluscum contagiosum from other skin lesions	S	SH

DR8.6	Enumerate the indications, describe the procedure and perform a Tzanck smear	S	SH
DR8.7	Enumerate the indications and describe the pharmacology, administration and adverse reaction of pharmacotherapies for common viral illnesses of the skin	K	KH

Topic: Leprosy

DR9.1	Classify, describe the epidemiology, etiology, microbiology, pathogenesis, clinical presentations and diagnostic features of Leprosy	K	KH
DR9.2	Demonstrate (and classify based on) the clinical features of leprosy including an appropriate neurologic examination		

		S	SH
DR9.3	Enumerate the indications and observe the performance of a slit skin smear in patients with leprosy	S	SH
DR9.4	Enumerate, describe and identify lepra reactions and supportive measures and therapy of lepra reactions	S	SH
DR9.5	Enumerate the indications and describe the pharmacology, administration and adverse reaction of pharmacotherapies for various classes of leprosy based on national guidelines	S	SH
DR9.6	Describe the treatment of Leprosy based on the WHO guidelines	S	SH
DR9.7	Enumerate and describe the complications of leprosy and its management, including understanding disability and stigma.	K	KH

--	--	--	--

Topic: Sexually Transmitted Disease

DR10.1	Identify and classify syphilis based on the presentation and clinical manifestations	S	SH
DR10.2	Identify spirochete in a dark ground microscopy	S	SH
DR10.3	Enumerate the indications and describe the pharmacology, administration and adverse reaction of pharmacotherapies for syphilis	K	KH
DR10.4	Describe the prevention of congenital syphilis	K	KH
DR10.5	Counsel in a non-judgemental and empathetic manner patients on prevention of sexually transmitted disease	C	SH
DR10.6	Describe the etiology, diagnostic and clinical features of non-syphilitic sexually transmitted diseases (chancroid, donovanosis and LGV)	K	KH

DR10.7	Identify and differentiate based on the clinical features non-syphilitic sexually transmitted diseases (chancroid, donovanosis and LGV)	S	SH
DR10.8	Enumerate the indications and describe the pharmacology, indications and adverse reactions of drugs used in the non-syphilitic sexually transmitted diseases (chancroid, donovanosis and LGV)	K	KH

DR10.9	Describe the syndromic approach to ulcerative sexually transmitted disease	K	KH
DR10.10	Describe the etiology, diagnostic and clinical features and management of gonococcal and non-gonococcal urethritis		
		K	KH
DR10.11	Describe the etiology, diagnostic and clinical features and management of vaginal discharge	K	KH

Topic: HIV

DR11.1	Describe the etiology, pathogenesis and clinical features of the dermatologic manifestations of HIV and its complications including opportunistic infections	K	KH
--------	--	---	----

DR11.2	Identify and distinguish the dermatologic manifestations of HIV, its complications, opportunistic infections and adverse reactions	S	SH
DR11.3	Enumerate the indications and describe the pharmacology, administration and adverse reaction of pharmacotherapies for dermatologic lesions in HIV	K	KH

Topic: Dermatitis and Eczema

DR12.1	Describe the aetiopathogenesis of eczema	K	KH
DR12.2	Identify eczema and differentiate it from lichenification and changes of aging	S	SH
DR12.3	Classify and grade eczema	K	KH
DR12.4	Enumerate the indications and describe the pharmacology, indications and adverse reactions of drugs used in the treatment of eczema		

		K	KH
DR12.5	Define erythroderma. Enumerate and identify the causes of erythroderma. Discuss the treatment	S	SH
DR12.6	Identify and distinguish exfoliative dermatitis from other skin lesions	S	SH
DR12.7	Identify and distinguish fixed drug eruptions and Steven Johnson syndrome from other skin lesions	S	SH
Topic: Vesicubullous Lesions		Number of competencies:(0	
DR13.1	Distinguish bulla from vesicles	S	SH

DR13.2	Demonstrate the Tzanck test, nikolsky sign and bulla spread sign	S	SH
DR13.3	Calculate the body surface area of involvement of vesiculobullous lesions	S	SH

Topic: Urticaria Angioedema

Number of competencies: (05)

DR14.1	Describe the etiology, pathogenesis and clinical precipitating features and classification of Urticaria and angioedema	K	KH
DR14.2	Identify and distinguish urticarial from other skin lesions	S	SH
DR14.3	Identify and distinguish urticarial from other skin lesions	S	SH
DR14.4	Identify and distinguish angioedema from other skin lesions	S	SH

DR14.5	Enumerate the indications and describe the pharmacology	K	KH

Topic: Pyoderma

Number of competencies: (04)

DR15.1	Identify and distinguish folliculitis impetigo and carbuncle from other skin lesions	S	SH
DR15.2	Identify staphylococcus on a gram stain	S	SH
DR15.3	Enumerate the indications and describe the pharmacology, indications and adverse reactions of topical and systemic drugs used in treatment of pyoderma	K	KH

DR15.4	Enumerate the indications for surgical referral	S	SH
Topic: Collagen Vascular disease		Number of competencies: (0/	
DR16.1	Identify and distinguish skin lesions of SLE	S	SH
DR16.2	Identify and distinguish Raynaud's phenomenon	S	SH
Topic: Nutritional Deficiencies and Skin		Number of competencies: (0/	
DR17.1	Enumerate and identify the cutaneous findings in vitamin A deficiency	K/S	SH
DR17.2	Enumerate and describe the various skin changes in Vitamin B complex deficiency	K	KH
DR17.4	Enumerate and describe the various changes in Vitamin C deficiency	K	KH

DR17.4	Enumerate and describe the various changes in Zinc deficiency	K	KH
--------	---	---	----

Topic: Systemic diseases and the skin **Number of competencies: (0**

DR18.1	Enumerate the cutaneous features of Type 2 diabetes	K	K
DR18.2	Enumerate the cutaneous features of hypo/hyper-thyroidism	K	K

Column C: K- Knowledge, S – Skill, A - Attitude / professionalism, C- Cor
Column D: K – Knows, KH - Knows How, SH - Shows how, P- performs in
Column H: If entry is P: indicate how many procedures mu

Number	COMPETENCY The student should be able to	Domain K/S/A/C	Level K/KH/SH/P
--------	--	-------------------	--------------------

AN4.2	Describe structure & function of skin with its appendages	K	KH
-------	---	---	----

AN4.4	Describe modifications of deep fascia with its functions	K	KH
-------	--	---	----

AN4.5	Explain principles of skin incisions	K	KH
-------	--------------------------------------	---	----

PA34.1	Describe the risk factors, pathogenesis, pathology and natural history of squamous cell carcinoma of the skin	K	KH
--------	---	---	----

PA34.2	Describe the risk factors, pathogenesis, pathology and natural history of basal cell carcinoma of the skin	K	KH
PA34.3	Describe the distinguishing features between a nevus and melanoma. Describe the etiology, pathogenesis, risk factors, morphology, clinical features and metastases of melanoma	K	KH
PA34.4	Identify, distinguish and describe common tumors of the skin	S	SH

MI4.3	Describe the etio-pathogenesis of Skin and soft tissue infections and discuss the clinical course, and the laboratory diagnosis.	K	KH
MI7.2	Describe the etio-pathogenesis and discuss the laboratory diagnosis of sexually transmitted infections. Recommend preventive measures, wherever relevant.	K	KH
PH1.46	Describe the mechanisms of action, types, doses, side effects, indications and contraindications of antileprotic drugs	K	KH
PH1.57	Describe drugs used in skin disorders	K	KH
PE31.4	Identify Atopic dermatitis and manage	S	SH

Core Y/N	Objectives	Date
----------	------------	------

i) Number of procedures that require certification:(NIL)

Y	A. At the end of the session the phase III student must be able to enumerate the causative factors in the etiology of acne.	01.04.2020
	B. At the end of the session the phase III student must be able to enumerate the risk factors of acne.	
Y	A. At the end of the session the phase III student must be able to identify the various morphological presentations of acne.	01.04.2020
	B. At the end of the session the phase III student must be able to enumerate the risk factors of acne.	
	C. At the end of the session the phase III student must be able to grade acne	
Y	A. At the end of the session the phase III student must be able to describe the various treatment modalities (topical, oral and physical) for the management of acne.	01.04.2020
	B. At the end of the session the phase III student must be able to describe the various preventive measures for acne.	

Number of competencies: (02)

Number of procedures that require certification: (02)

Y	A. At the end of the session the phase III student must be able to identify the clinical lesions of Vitiligo.	04.04.2020
	B. At the end of the session the phase III student must be able to enumerate different causes of hypopigmented lesions.	
	C. At the end of the session the phase III student must be able to differentiate vitiligo from other causes of hypopigmented lesions.	
Y	A. At the end of the session the phase III student must be able to describe the medical treatment of Vitiligo	04.04.2020
	B. At the end of the session the phase III student must be able to describe the use of phototherapy in treatment of Vitiligo	
	C. At the end of the session the phase III student must be able to enumerate the various surgical modalities for the treatment of vitiligo	

Number of competencies:(03)

Number of procedures that require certification:(NIL)

Y	A. At the end of the session the phase III student must be able to clinically identify a plaque of psoriasis	08.04.2020
	B. At the end of the session the phase III student must be able to enumerate differential diagnosis of psoriatic lesion	
	C. At the end of the session the phase III student must be able to justify the diagnosis of a psoriatic lesion and distinguish it from other causes	
Y	A. At the end of the session the phase III student must be able to list the three stages of the Auspitz sign and correctly demonstrate the grattage test	08.04.2020

Y	A. At the end of the session the phase III student must be able to clinically identify the lesions of scabies in children	18.04.2020
	B. At the end of the session the phase III student must be able to clinically identify the lesions of scabies in adults	
	C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of scabies in children	
	D. At the end of the session the phase III student must be able to enumerate the differential diagnosis of scabies in adults	18.04.2020
	E. At the end of the session the phase III student must be able to clinically diagnose scabies and clinically differentiate from other causes in children	
	F. At the end of the session the phase III student must be able to diagnose scabies and clinically differentiate the lesions of scabies from other causes in adults	
Y	A. At the end of the session the phase III student must be able to enumerate various treatment options for the treatment of scabies	18.04.2020
	B. At the end of the session the phase III student must be able to describe the pharmacology of permethrin and ivermectin in scabies	
	C. At the end of the session the phase III student must be able to describe the correct mode of administration of various topical and oral drugs used for the treatment of scabies	
	D. At the end of the session the phase III student must be able to describe the adverse reactions to the pharmacotherapies for scabies	

Number of competencies : (02)

Number of procedures that

Y	A. At the end of the session the phase III student must be able to describe the etiology of pediculosis	22.04.2020
	B. At the end of the session the phase III student must be able to describe the pathogenesis of pediculosis	
	C. At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in adults	
	D. At the end of the session the phase III student must be able to describe the diagnostic features of pediculosis in children	
Y	A. At the end of the session the phase III student must be able to describe the types of pediculosis and clinically identify the skin lesions of pediculosis capitis	22.04.2020
	B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of pediculosis capitis in children	
	C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of pediculosis capitis in	
	D. At the end of the session the phase III student must be able to clinically differentiate the lesions of pediculosis capitis from other causes	

Number of competencies: (03)		Number of pro
Y	A. At the end of the session the phase III student must be able to describe the etiology of dermatophytes	25.04.2020
	B. At the end of the session the phase III student must be able to describe the microbiology of dermatophytes	
	C. At the end of the session the phase III student must be able to describe the pathogenesis of dermatophytes	
	D. At the end of the session the phase III student must be able to describe the clinical presentations of dermatophytes in children	
	E. At the end of the session the phase III student must be able to describe the clinical presentations of dermatophytes in adults	
	F. At the end of the session the phase III student must be able to describe the diagnostic features of dermatophytes in adults	25.04.2020
	G. At the end of the session the phase III student must be able to describe the diagnostic features of dermatophytes in children	25.04.2020
Y	H. At the end of the session the phase III student must be able to identify <i>Candida</i> species in fungal scrapings and KOH mount	25.04.2020
Y	I. At the end of the session the phase III student must be able to describe the pharmacology of systemic antifungal agents	25.04.2020
		25.04.2020
	J. At the end of the session the phase III student must be able to describe the pharmacology of topical antifungal agents	25.04.2020
	K. At the end of the session the phase III student must be able to describe the mechanism of action of systemic antifungal agents	25.04.2020
	L. At the end of the session the phase III student must be able to describe the mechanism of action of topical antifungal agents	25.04.2020
	M. At the end of the session the phase III student must be able to enumerate the side effects of antifungal therapy	25.04.2020

Number of competencies (07)		Number of pro
Y	A. At the end of the session the phase III student must be able to describe the etiology of common viral infections which include varicella zoster, herpes simplex, viral warts and molluscum contagiosum	29.04.2020
	B. At the end of the session the phase III student must be able to describe the microbiology of common viral infections of the skin	29.04.2020
	C. At the end of the session the phase III student must be able to describe the pathogenesis of the common viral infections of the skin	29.04.2020

	D. At the end of the session the phase III student must be able to describe the clinical presentations of common viral infections of the skin in children	29.04.2020
	E. At the end of the session the phase III student must be able to describe the clinical presentations of common viral infections of the skin in adults	29.04.2020
		29.04.2020
	F. At the end of the session the phase III student must be able to describe the diagnostic features of common viral infections of the skin in children	29.04.2020
Y	A. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes simplex	29.04.2020
	B. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes labialis	29.04.2020
	C. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes simplex	29.04.2020
		29.04.2020
	D. At the end of the session the phase III student must be able to justify the diagnosis of herpes simplex and distinguish lesions of herpes simplex from other skin lesions	29.04.2020
Y	E. At the end of the session the phase III student must be able to clinically identify the skin lesions of herpes zoster	29.04.2020
	F. At the end of the session the phase III student must be able to clinically identify the skin lesions of primary varicella	29.04.2020
	G. At the end of the session the phase III student must be able to enumerate the differential diagnosis of herpes zoster	29.04.2020
	H. At the end of the session the phase III student must be able to enumerate the differential diagnosis of varicella	29.04.2020
	I. At the end of the session the phase III student must be able to justify the diagnosis of herpes zoster and differentiate the skin lesions of herpes zoster from other skin lesions	29.04.2020
		29.04.2020
Y	A. At the end of the session the phase III student must be able to clinically identify the skin lesions of viral warts	29.04.2020
	B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of viral warts	29.04.2020
	C. At the end of the session the phase III student must be able to justify the diagnosis of viral warts and be able to distinguish viral warts from other skin lesions	29.04.2020
Y	D. At the end of the session the phase III student must be able to clinically identify the skin lesions of molluscum contagiosum	29.04.2020
	E. At the end of the session the phase III student must be able to enumerate the differential diagnosis of molluscum contagiosum	29.04.2020
		29.04.2020

	F. At the end of the session the phase III student must be able to justify the diagnosis of molluscum contagiosum and distinguish molluscum contagiosum from other skin lesions	29.04.2020
Y	A. At the end of the session the phase III student must be able to enumerate the indications of tzanck smear	29.04.2020
	B. At the end of the session the phase III student must be able to describe the procedure to perform a tzanck smear	29.04.2020
	C. At the end of the session the phase III student must be able to perform a tzanck smear	29.04.2020
Y	A. At the end of the session the phase III student must be able to enumerate the indications for pharmacotherapies and physical modalities for common viral illnesses of the skin	29.04.2020
	B. At the end of the session the phase III student must be able to describe the pharmacology of pharmacotherapies and physical modalities for common viral illnesses of the skin	29.04.2020
		29.04.2020
	C. At the end of the session the phase III student must be able to describe the mode of administration of pharmacotherapies and physical modalities for common viral illnesses of the skin	29.04.2020
D. At the end of the session the phase III student must be able to describe the adverse reactions of pharmacotherapies and physical modalities for common viral illnesses of the skin	29.04.2020	

Number of competencies: (07)

Number of prc

Y	A. At the end of the session the phase III student must be able to describe the epidemiology of leprosy	02.05.2020
	B. At the end of the session the phase III student must be able to describe the etiology of leprosy	
	C. At the end of the session the phase III student must be able to describe the microbiology of leprosy	
	D. At the end of the session the phase III student must be able to describe the clinical presentations of leprosy and classify the spectrum of leprosy	02.05.2020
	E. At the end of the session the phase III student must be able to describe the diagnostic features of leprosy	
	F. At the end of the session the phase III student must be able to demonstrate the clinical features of leprosy	
	G. At the end of the session the phase III student must be able to classify leprosy according to the Ridley Jopling classification	

Y	based on the clinical features	
	H. At the end of the session the phase III student must be able to demonstrate an appropriate neurological examination on a patient of leprosy	02.05.2020
Y	A. At the end of the session the phase III student must be able to enumerate the indications for performing a slit skin smear in patients with leprosy	02.05.2020
	B. At the end of the session the phase III student must be able to enumerate the steps and observe the performance of a slit skin smear in patients with leprosy	02.05.2020
Y	A. At the end of the session the phase III student must be able to enumerate the types of lepra reaction	02.05.2020
	B. At the end of the session the phase III student must be able to describe the clinical features of of lepra reactions	
	C. At the end of the session the phase III student must be able to clinically identify the types of lepra reactions	
	D. At the end of the session the phase III student must be able to describe the supportive measures for the management of lepra reactions	
	E. At the end of the session the phase III student must be able to describe the pharmacotherapy of lepra reactions	
Y	A. At the end of the session the phase III student must be able to enumerate the indications of pharmacotherapies for various classes of leprosy based on national guidelines	02.05.2020
	B. At the end of the session the phase III student must be able to describe the pharmacology of pharmacotherapies for various classes of leprosy based on national guidelines	02.05.2020
	C. At the end of the session the phase III student must be able to describe the administration of pharmacotherapies for various classes of leprosy based on national guidelines	02.05.2020
	D. At the end of the session the phase III student must be able to describe the adverse reaction of pharmacotherapies for various classes of leprosy based on national guidelines	02.05.2020
Y	A. At the end of the session the phase III student must be able to describe the treatment of Leprosy based on the WHO guidelines	02.05.2020
Y	A. At the end of the session the phase III student must be able to enumerate the complications of leprosy	02.05.2020
	B. At the end of the session the phase III student must be able to describe the complications of leprosy	02.05.2020
	C. At the end of the session the phase III student must be able to describe the management of complications of leprosy	02.05.2020

	D. At the end of the session the phase III student must be able to describe the disabilities associated with leprosy	02.05.2020
	E. At the end of the session the phase III student must be able to understand the stigma associated with leprosy	02.05.2020

ases	Number of competencies: (11)	Number of proc
Y	A. At the end of the session the phase III student must be able to identify a clinical case of syphilis	06.05.2020
	B. At the end of the session the phase III student must be able to classify the stage of syphilis based on clinical presentation	06.05.2020
	C. At the end of the session the phase III student must be able to describe the clinical manifestations of syphilis	06.05.2020
Y	D. At the end of the session the phase III student must be able to identify spirochete in a dark ground microscopy	06.05.2020
Y	E. At the end of the session the phase III student must be able to enumerate the indications of pharmacotherapies for syphilis	06.05.2020
	F. At the end of the session the phase III student must be able to describe the pharmacology of pharmacotherapies for syphilis	06.05.2020
	G. At the end of the session the phase III student must be able to describe the administration of pharmacotherapies for syphilis	06.05.2020
	H. At the end of the session the phase III student must be able to describe the adverse reaction of pharmacotherapies for	06.05.2020
Y	A. At the end of the session the phase III student must be able to describe the prevention of congenital syphilis	06.05.2020
Y	A. At the end of the session the phase III student must be able to counsel in a non-judgemental and empathetic manner patients on prevention of sexually transmitted disease	06.05.2020
Y	A. At the end of the session the phase III student must be able to describe the etiology of chancroid	06.05.2020
	B. At the end of the session the phase III student must be able to describe the diagnostic features of chancroid	06.05.2020
	C. At the end of the session the phase III student must be able to describe the clinical features of chancroid	06.05.2020
	D. At the end of the session the phase III student must be able to describe the etiology of donovanosis	06.05.2020
	E. At the end of the session the phase III student must be able to describe the diagnostic features of donovanosis	06.05.2020
	F. At the end of the session the phase III student must be able to describe the clinical features of donovanosis	06.05.2020
	G. At the end of the session the phase III student must be able to describe the etiology of LGV	06.05.2020

	H.At the end of the session the phase III student must be able to describe the diagnostic features of LGV	06.05.2020
	I.At the end of the session the phase III student must be able to describe the clinical features of LGV	06.05.2020
Y	A. At the end of the session the phase III student must be able to clinically identify the lesions of chancroid	06.05.2020
	B. At the end of the session the phase III student must be able to clinically identify the lesions of donovanosis	06.05.2020
	C. At the end of the session the phase III student must be able to clinically identify the lesions of LGV	06.05.2020
	DE.At the end of the session the phase III student must be able to differentiate chancroid from other non-syphilitic sexually transmitted diseases	06.05.2020
	E.At the end of the session the phase III student must be able to differentiate donovanosis from other non-syphilitic sexually transmitted diseases	06.05.2020
	F. At the end of the session the phase III student must be able to differentiate LGV from other non-syphilitic sexually transmitted diseases	06.05.2020
Y	A. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of chancroid	06.05.2020
	B. At the end of the session the phase III student must be able	06.05.2020
	C. to describe the pharmacology of drugs used for the management of chancroid	06.05.2020
	D. At the end of the session the phase III student must be able to describe the administration of drugs used for the management of chancroid	06.05.2020
	E. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of chancroid	06.05.2020
	F. At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of donovanosis	06.05.2020
	G. At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of donovanosis	06.05.2020
	H.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of donovanosis	06.05.2020
	I. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of donovanosis	06.05.2020
	J.At the end of the session the phase III student must be able to enumerate the indications for use of drugs for the management of LGV	06.05.2020
	K.At the end of the session the phase III student must be able to describe the pharmacology of drugs used for the management of LGV	06.05.2020

	L.At the end of the session the phase III student must be able to describe the administration of drugs used for the management of LGV	06.05.2020
	M. At the end of the session the phase III student must be able to describe the adverse effects of drugs used for the management of LGV	06.05.2020
Y	A. At the end of the session the phase III student must be able to enumerate the ulcerative sexually transmitted diseases	06.05.2020
	B. At the end of the session the phase III student must be able to describe the syndromic approach to ulcerative sexually transmitted disease	06.05.2020
	C. At the end of the session the phase III student must be able to describe the etiology of gonococcal urethritis	06.05.2020
Y	D. At the end of the session the phase III student must be able to describe the etiology of non-gonococcal urethritis	06.05.2020
	E. At the end of the session the phase III student must be able to describe the diagnostic features of gonococcal urethritis	06.05.2020
	F. At the end of the session the phase III student must be able to describe the diagnostic features of non-gonococcal urethritis	06.05.2020
	G. At the end of the session the phase III student must be able to describe the clinical features of gonococcal urethritis	06.05.2020
	H.At the end of the session the phase III student must be able to describe the clinical features of non-gonococcal urethritis	06.05.2020
	I.At the end of the session the phase III student must be able to describe the management of gonococcal urethritis	06.05.2020
	J.At the end of the session the phase III student must be able to describe the management of non-gonococcal urethritis	06.05.2020
Y	A.At the end of the session the phase III student must be able to describe the etiology of vaginal discharge	06.05.2020
	B. At the end of the session the phase III student must be able to describe the various causes of vaginal discharge	06.05.2020
	C.At the end of the session the phase III student must be able to describe the clinical features of the various causes of vaginal discharge	06.05.2020
	D.At the end of the session the phase III student must be able to describe the management of the pathological causes of vaginal discharge	06.05.2020
Number of competencies: (03)		Number of proc
Y	A.At the end of the session the phase III student must be able to describe the etiology of HIV	09.05.2020
	B.At the end of the session the phase III student must be able to describe the pathogenesis of HIV	09.05.2020

	C. At the end of the session the phase III student must be able to describe the clinical features of the dermatologic manifestations of HIV	09.05.2020
		09.05.2020
	D. At the end of the session the phase III student must be able to describe the complications of HIV	09.05.2020
	E. At the end of the session the phase III student must be able to describe the opportunistic infections associated with HIV	09.05.2020
Y	A. At the end of the session the phase III student must be able to clinically identify the dermatological manifestations of HIV	09.05.2020
	B. At the end of the session the phase III student must be able to clinically distinguish the dermatological manifestations of HIV from other causes	09.05.2020
	C. At the end of the session the phase III student must be able to clinically identify the complications of HIV	09.05.2020
	D. At the end of the session the phase III student must be able to clinically identify the opportunistic infections associated with HIV	09.05.2020
	E. At the end of the session the phase III student must be able to distinguish the adverse reactions associated with management of HIV	09.05.2020
Y	A. At the end of the session the phase III student must be able to enumerate the indications of pharmacotherapies for dermatologic lesions in HIV	09.05.2020
	B. At the end of the session the phase III student must be able to describe the pharmacology of pharmacotherapies for dermatologic lesions in HIV	09.05.2020
	C. At the end of the session the phase III student must be able to describe the administration of pharmacotherapies for dermatologic lesions in HIV	09.05.2020
	D. At the end of the session the phase III student must be able to describe the adverse effects of pharmacotherapies for dermatologic lesions in HIV	09.05.2020

Number of competencies: (07)

Number of pr

Y	A. At the end of the session the phase III student must be able to describe the aetiopathogenesis of eczema	13.05.2020
Y	B. At the end of the session the phase III student must be able to clinically identify the cutaneous lesions of eczema	13.05.2020
	C. At the end of the session the phase III student must be able to differentiate eczema from lichenification	
	D. At the end of the session the phase III student must be able to differentiate eczema from changes of aging	13.05.2020
Y	A. At the end of the session the phase III student must be able to classify eczema	
	B. At the end of the session the phase III student must be able to grade eczema	13.05.2020
	A. At the end of the session the phase III student must be able to enumerate the indications of drugs used in the treatment of eczema	13.05.2020

Y	B. At the end of the session the phase III student must be able to describe the pharmacology of drugs used in the treatment of eczema	
	C. At the end of the session the phase III student must be able to describe the topical and systemic administration of drugs used in the treatment of eczema	
	D. At the end of the session the phase III student must be able to describe the adverse reactions of drugs used in the treatment of eczema	
Y	A. At the end of the session the phase III student must be able to define erythroderma	13.05.2020
	B. At the end of the session the phase III student must be able to enumerate the causes of erythroderma	13.05.2020
	C. At the end of the session the phase III student must be able to identify the causes of erythroderma	13.05.2020
	D. At the end of the session the phase III student must be able to describe the topical and systemic treatment of the various types of erythroderma	13.05.2020
Y	A. At the end of the session the phase III student must be able to clinically identify exfoliative dermatitis	13.05.2020
	B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of exfoliative dermatitis	13.05.2020
	C. At the end of the session the phase III student must be able to distinguish exfoliative dermatitis from other skin lesions	13.05.2020
Y	A. At the end of the session the phase III student must be able to identify the lesions of fixed drug eruptions	13.05.2020
	B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of fixed drug eruptions	
	C. At the end of the session the phase III student must be able to distinguish fixed drug eruptions from other skin lesions	
	D. At the end of the session the phase III student must be able to identify the skin lesions of Steven Johnson syndrome	
	E. At the end of the session the phase III student must be able to enumerate the differential diagnosis of Steven Johnson syndrome	
	F. At the end of the session the phase III student must be able to distinguish Steven Johnson syndrome from other skin lesions	
3) Number of procedures that require certificaion:(NIL)		
Y	A. At the end of the session the phase III student must be able to define a vesicle	16.05.2020
	B. At the end of the session the phase III student must be able to define a bulla	16.05.2020

	C. At the end of the session the phase III student must be able to distinguish a bulla from vesicle	16.05.2020
Y	A. At the end of the session the phase III student must be able to demonstrate a tzanck smear	16.05.2020
	B. At the end of the session the phase III student must be able to demonstrate nikolsky sign	
	C. At the end of the session the phase III student must be able to demonstrate bulla spread sign	
Y	D. At the end of the session the phase III student must be able to calculate the body surface area of involvement of vesiculobullous lesions	16.05.2020

5) **Number of procedures that require certificaion:(NIL)**

Y	A. At the end of the session the phase III student must be able to describe the etiology of urticaria	20.05.2020
	B. At the end of the session the phase III student must be able to describe the pathogenesis of urticaria	20.05.2020
	C. At the end of the session the phase III student must be able to describe the clinical features of urticaria	20.05.2020
	D. At the end of the session the phase III student must be able to describe the precipitating factors for urticaria	20.05.2020
	E. At the end of the session the phase III student must be able to describe the classification of urticaria	20.05.2020
	F. At the end of the session the phase III student must be able to describe the etiology of angioedema	20.05.2020
	G. At the end of the session the phase III student must be able to describe the pathogenesis of angioedema	20.05.2020
	H. At the end of the session the phase III student must be able to describe the clinical features of angioedema	20.05.2020
	I. At the end of the session the phase III student must be able to describe the precipitating factors of angioedema	20.05.2020
	J. At the end of the session the phase III student must be able to describe the classification of angioedema	20.05.2020
Y	A. At the end of the session the phase III student must be able to clinically identify the cutaneous lesions of urticaria	20.05.2020
	B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of urticaria	20.05.2020
	C. At the end of the session the phase III student must be able to distinguish urticaria from other skin lesions	20.05.2020
Y	A. At the end of the session the phase III student must be able to demonstrate dermographism	20.05.2020
Y	A. At the end of the session the phase III student must be able to clinically identify the lesions of angioedema	20.05.2020
		20.05.2020
	B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of angioedema	20.05.2020

	C. At the end of the session the phase III student must be able to distinguish angioedema from other skin lesions	20.05.2020
Y	A. At the end of the session the phase III student must be able to enumerate the indications of drugs used in the management of urticaria	20.05.2020
	B. At the end of the session the phase III student must be able to describe the pharmacology of drugs used in the management of urticaria	20.05.2020
	C. At the end of the session the phase III student must be able to describe the administration of drugs used in the management of urticaria	20.05.2020
	D. At the end of the session the phase III student must be able to describe the adverse reactions of drugs used in the management of urticaria	20.05.2020
	E. At the end of the session the phase III student must be able to enumerate the indications of drugs used in the management of angioedema	20.05.2020
	F. At the end of the session the phase III student must be able to describe the pharmacology of drugs used in the management of angioedema	20.05.2020
	G. At the end of the session the phase III student must be able to describe the administration of drugs used in the management of angioedema	20.05.2020

) **Number of procedures that require certificaion:(NIL)**

Y	A. At the end of the session the phase III student must be able to identify the cutaneous lesions of folliculitis	23.05.2020
	B. At the end of the session the phase III student must be able to identify the cutaneous lesions of impetigo	23.05.2020
	C. At the end of the session the phase III student must be able to identify the cutaneous lesions of carbuncle	23.05.2020
	D. At the end of the session the phase III student must be able to distinguish the cutaneous lesions of folliculitis from other skin lesions	23.05.2020
	E. At the end of the session the phase III student must be able to distinguish the cutaneous lesions of impetigo from other skin lesions	23.05.2020
		23.05.2020
F. At the end of the session the phase III student must be able to distinguish the cutaneous lesions of carbuncle from other skin lesions	23.05.2020	
Y	A. At the end of the session the phase III student must be able to identify staphylococcus on a gram stain	23.05.2020
Y	A. At the end of the session the phase III student must be able to list the topical drugs used in treatment of pyoderma and describe the indications of the topical drugs in pyoderma	23.05.2020
	B. At the end of the session the phase III student must be able to describe the pharmacology of topical drugs used in treatment of pyoderma	23.05.2020
	C. At the end of the session the phase III student must be able to describe the administration of topical drugs used in treatment of pyoderma	23.05.2020

	D. At the end of the session the phase III student must be able to describe the adverse reactions of topical drugs used in treatment of pyoderma	23.05.2020
	E. At the end of the session the phase III student must be able to enumerate the indications of systemic drugs used in treatment of pyoderma	23.05.2020
	F. At the end of the session the phase III student must be able to describe the pharmacology of systemic drugs used in treatment of pyoderma	23.05.2020
	G. At the end of the session the phase III student must be able to describe the administration of systemic drugs used in treatment of pyoderma	23.05.2020
	H. At the end of the session the phase III student must be able to describe the adverse reactions of systemic drugs used in treatment of pyoderma	23.05.2020
Y	A. At the end of the session the phase III student must be able to enumerate the indications for surgical referral.	23.05.2020

2) Number of procedures that require certification:(NIL)

Y	A. At the end of the session the phase III student must be able to identify the skin lesions of SLE	27.05.2020
	B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of the cutaneous manifestations of SLE	27.05.2020
	C. At the end of the session the phase III student must be able to distinguish the skin lesions of SLE from other skin lesions	27.05.2020
Y	A. At the end of the session the phase III student must be able to describe the three phases and identify Raynaud's phenomenon	27.05.2020
	B. At the end of the session the phase III student must be able to enumerate the differential diagnosis of Raynaud's phenomenon	27.05.2020
	C. At the end of the session the phase III student must be able to distinguish the various causes of Raynaud's phenomenon	27.05.2020

4) Number of procedures that require certification:(NIL)

Y	A. At the end of the session the phase III student must be able to enumerate the cutaneous findings in vitamin A deficiency	30.05.2020
	B. At the end of the session the phase III student must be able to identify the cutaneous findings in vitamin A deficiency	30.05.2020
Y	A. At the end of the session the phase III student must be able to enumerate the various skin changes in Vitamin B complex deficiency	30.05.2020
	B. At the end of the session the phase III student must be able to describe the various skin changes in Vitamin B complex deficiency	30.05.2020
Y	A. At the end of the session the phase III student must be able to enumerate the various changes in Vitamin C deficiency	30.05.2020
	B. At the end of the session the phase III student must be able to describe the various changes in Vitamin C deficiency	30.05.2020

Y	A. At the end of the session the phase III student must be able to enumerate the various skin changes in Zinc deficiency	30.05.2020
	B. At the end of the session the phase III student must be able to describe the various skin changes in Zinc deficiency	30.05.2020

2) Number of procedures that require certification:(NIL)

Y	A. At the end of the session the phase III student must be able to enumerate the cutaneous features of Type 2 diabetes	03.06.2020
Y	B. At the end of the session the phase III student must be able to enumerate the cutaneous features of hypo/hyper-thyroidism	03.06.2020

Communication.

Independently, Column F: DOAP session – Demonstrate, Observe, Assess, Perform.

Must be done independently for certification/ graduation

Integration

Core (Y/N)		Suggested Teaching Learning method
------------	--	------------------------------------

Human Anatomy

Y	A. At the end of the session the phase III student must be able to describe the structure of skin	Lecture, DOAP session
	B. At the end of the session the phase III student must be able to describe the structure of skin appendages	Lecture, DOAP session
	C. At the end of the session the phase III student must be able to describe the functions of skin	Lecture, DOAP session
	D. At the end of the session the phase III student must be able to describe the functions of the skin appendages	Lecture, DOAP session
Y	A. At the end of the session the phase III student must be able to describe the modifications of deep fascia	Lecture, DOAP session
	B. At the end of the session the phase III student must be able to describe the functions of deep fascia	Lecture, DOAP session
N	A. At the end of the session the phase III student must be able to explain the principles of skin incisions	Lecture

Pathology

Y	A. At the end of the session the phase III student must be able to describe the risk factors of squamous cell carcinoma of the skin	Lecture, Small group discussion
	B. At the end of the session the phase III student must be able to describe the pathogenesis of squamous cell carcinoma of the skin	Lecture, Small group discussion
		Lecture, Small group discussion

	C. At the end of the session the phase III student must be able to describe the pathology of squamous cell carcinoma of the skin	Lecture, Small group discussion
	D. At the end of the session the phase III student must be able to describe the natural history of squamous cell carcinoma of the skin	Lecture, Small group discussion
Y	A. At the end of the session the phase III student must be able to describe the risk factors of basal cell carcinoma of the skin	Lecture, Small group discussion
	B. At the end of the session the phase III student must be able to describe the pathogenesis of basal cell carcinoma of the skin	Lecture, Small group discussion
	C. At the end of the session the phase III student must be able to describe the pathology of basal cell carcinoma of the skin	Lecture, Small group discussion
	D. At the end of the session the phase III student must be able to describe the natural history of basal cell carcinoma of the skin	Lecture, Small group discussion
	E. At the end of the session the phase III student must be able to describe the pathology of basal cell carcinoma of the skin	Lecture, Small group discussion
	F. At the end of the session the phase III student must be able to describe the natural history of basal cell carcinoma of the skin	Lecture, Small group discussion
N	A. At the end of the session the phase III student must be able to describe the clinical distinguishing features between a nevus and melanoma	Lecture, Small group discussion
	B. At the end of the session the phase III student must be able to describe the etiology of melanoma	Lecture, Small group discussion
	C. At the end of the session the phase III student must be able to describe the pathogenesis of melanoma	Lecture, Small group discussion
	D. At the end of the session the phase III student must be able to describe the risk factors of melanoma	Lecture, Small group discussion
	E. At the end of the session the phase III student must be able to describe the various morphological presentations of melanoma	Lecture, Small group discussion
	F. At the end of the session the phase III student must be able to describe the clinical features of melanoma	Lecture, Small group discussion
	G. At the end of the session the phase III student must be able to describe the metastases of melanoma	Lecture, Small group discussion
N	A. At the end of the session the phase III student must be able to enumerate the common skin tumors	DOAP session
	B. At the end of the session the phase III student must be able to identify the common skin tumors	DOAP session
	C. At the end of the session the phase III student must be able to distinguish the common skin tumors	DOAP session

	D. At the end of the session the phase III student must be able to describe the common skin tumors	DOAP session
--	---	--------------

Microbiology

Y	A. At the end of the session the phase III student must be able to describe the etio-pathogenesis of Skin and soft tissue infections	Lecture
	B. At the end of the session the phase III student must be able to describe the clinical course of Skin and soft tissue infections	Lecture
	C. At the end of the session the phase III student must be able to describe the laboratory diagnosis of Skin and soft tissue infections	Lecture
Y	A. At the end of the session the phase III student must be able to describe the etio-pathogenesis of sexually transmitted infections	Lecture, Small group discussion
	B. At the end of the session the phase III student must be able to describe the laboratory diagnosis of sexually transmitted infections	Lecture, Small group discussion
	C. At the end of the session the phase III student must be able to describe the preventive measures of sexually transmitted infections	Lecture, Small group discussion

Pharmacology

Y	A. At the end of the session the phase III student must be able to describe the mechanism of action of antileprotic drugs	Lecture
	B. At the end of the session the phase III student must be able to describe the types of antileprotic drugs	Lecture
	C. At the end of the session the phase III student must be able to describe the doses of antileprotic drugs	Lecture
	D. At the end of the session the phase III student must be able to describe the side effects of antileprotic drugs	Lecture
	E. At the end of the session the phase III student must be able to describe the indications of antileprotic drugs	Lecture
	F. At the end of the session the phase III student must be able to describe the contraindications of antileprotic drugs	Lecture
Y	G. At the end of the session the phase III student must be able to describe the common drugs used in skin disorders	Lecture

Pediatrics

	A. At the end of the session the phase III student must be able to identify atopic dermatitis and justify the diagnosis	Bedside clinics, Skill Lab
	B. At the end of the session the phase III student must be able to manage a case of atopic dermatitis	Bedside clinics

Time	Suggested Teaching Learning methods	Suggested Assessment methods	Number required to certify P	Vertical integration	Horizontal Integration
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
require certificaion:(NIL)					
08.30 to 9.30	Bedside clinic	Skill assessment			
	Lecture, Small group discussion	Written/ Viva voce			
	Bedside clinic	Skill assessment			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion and demonstration	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Skill assessment/ Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Skill assessment			

08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			

08.30 to 9.30	Bedside clinic	Skill assessment			
	Lecture, Small group discussion	Written/ Viva voce			
	Bedside clinic	Skill assessment			

08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			

cedures that require certificaion:(NIL)

08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			

08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
---------------	---------------------------------	--------------------	--	--	--

08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
---------------	---------------------------------	--------------------	--	--	--

08.30 to 9.30					
---------------	--	--	--	--	--

08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Skill assessment			
08.30 to 9.30	Bedside clinic	Skill assessment			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			

require certificaion:(NIL)

08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Skill assessment			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Bedside clinic	Skill assessment			

cedures that require certificaion:(NIL)

08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	DOAP session	Skill assessment			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			

cedures that require certification: (NIL)

08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			

	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	DOAP session	Skill assessment			
08.30 to 9.30	DOAP session	Skill assessment			
08.30 to 9.30	Lecture, Small group discussion	Skill assessment/ Written/ Viva voce			
08.30 to 9.30					
08.30 to 9.30	DOAP session	Skill assessment			
	DOAP session	Skill assessment			
	DOAP session	Skill assessment			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	DOAP session	Skill assessment			
08.30 to 9.30					
	DOAP session	Skill assessment			
	DOAP session	Skill assessment			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	DOAP session	Skill assessment			
	DOAP session	Skill assessment			

	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	DOAP session	Skill assessment			
	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	DOAP session	skill assesment			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
cedures that require certificaion:(NIL)					
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small	Written/ Viva			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Bedside clinic/ Skill assessment			
08.30 to 9.30	Bedside clinic	Bedside clinic/ Skill assessment			

08.30 to 9.30	Bedside clinic	Bedside clinic/ Skill assessment			
08.30 to 9.30	Bedside clinic	Bedside clinic/ Skill assessment			
08.30 to 9.30	Bedside clinic, DOAP session	Written/ Viva voce			
	Bedside clinic, DOAP session	Skill assessment			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Bedside clinic	Bedside clinic			
	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			

08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
08.30 to 9.30	Bedside clinic	Skill assessment			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			

Procedures that require certification:(NIL)

08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Skill assessment			
08.30 to 9.30	Bedside clinic	Skill assessment			
08.30 to 9.30	Bedside clinic	Skill assessment			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			

	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Written/ Skill assessment			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Skill assessment			
08.30 to 9.30	Lecture, Small group discussion, Bedside clinic	Skill assessment, Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Skill assessment			
08.30 to 9.30	Bedside clinic	Skill assessment			
	Lecture, Small group discussion	Written/ Viva voce, Skill			
	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
	Lecture, Small group discussion	Skill assessment, Written/ Viva voce,			
	Bedside clinic	Skill assessment			
<hr/>					
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			

	Bedside clinic	Skill assessment			
08.30 to 9.30	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
08.30 to 9.30	Bedside clinic	Skill assessment			

08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Skill assessment			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Skill assessment			
08.30 to 9.30	Bedside clinic	Skill assessment			
08.30 to 9.30	Bedside clinic	Skill assessment			
	Lecture, Small group discussion	Skill assessment. Written/ Viva voce			

	Bedside clinic	Skill assessment			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			

08.30 to 9.30	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
	Bedside clinic	Skill assessment			
08.30 to 9.30	Bedside clinic	Skill assessment			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			

08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	DOAP session	Written/ Viva voce			
08.30 to 9.30	Bedside clinic	Skill assessment			
	Lecture, small group discussion	Written/ Viva voce			
	Bedside clinic	Skill assessment			
08.30 to 9.30	Bedside clinic	Skill assessment			
	Lecture, small group discussion	Written/ Viva voce			
	Bedside clinic	Skill assessment			
08.30 to 9.30	Lecture, Small group discussion	Skill assessment/ Viva voce			
	Lecture, Small group discussion	Skill assessment/ Viva voce			
08.30 to 9.30	Bedside clinic	Skill assessment			
	Lecture	Written/ Viva voce			
08.30 to 9.30	Lecture	Written/ Viva voce			
	Lecture	Written/ Viva voce			

08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group discussion	Written/ Viva voce			
08.30 to 9.30	Lecture, Small group	Written/ Viva voce			

Suggested Assessment method	Number required to certify P	Vertical Integration	Horizontal Integration		
Written/ Viva voce		Dermatology, Venereology & Leprosy			
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce		Dermatology, Venereology & Leprosy			
Written/ Viva voce					
Written		Dermatology, Venereology & Leprosy			
Written/ Viva voce		Dermatology, Venereology & Leprosy			
Written/ Viva voce					
Written/ Viva voce					

Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce		Dermatology, Venereology & Leprosy			
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce		Dermatology, Venereology &			
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce					
Skill Assessment		Dermatology, Venereology & Leprosy			
Skill Assessment					
Skill Assessment					

Skill Assessment					
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce		Dermatology, Venereology & Leprosy	Microbiology		
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce					
Written/ Viva voce		Dermatology, Venereology & Leprosy			
Skill Assessment		Dermatology, Venereology & Leprosy			
Bedside clinics					